Literature DB >> 26348965

Principles of nanoparticle design for overcoming biological barriers to drug delivery.

Elvin Blanco1, Haifa Shen1,2, Mauro Ferrari1,3.   

Abstract

Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26348965      PMCID: PMC4978509          DOI: 10.1038/nbt.3330

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  118 in total

1.  Shape effects of filaments versus spherical particles in flow and drug delivery.

Authors:  Yan Geng; Paul Dalhaimer; Shenshen Cai; Richard Tsai; Manorama Tewari; Tamara Minko; Dennis E Discher
Journal:  Nat Nanotechnol       Date:  2007-03-25       Impact factor: 39.213

2.  Quantitative profiling of the protein coronas that form around nanoparticles.

Authors:  Dominic Docter; Ute Distler; Wiebke Storck; Jörg Kuharev; Desirée Wünsch; Angelina Hahlbrock; Shirley K Knauer; Stefan Tenzer; Roland H Stauber
Journal:  Nat Protoc       Date:  2014-07-31       Impact factor: 13.491

3.  Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.

Authors:  Ho Lun Wong; Reina Bendayan; Andrew Mike Rauth; Xiao Yu Wu
Journal:  J Control Release       Date:  2006-09-26       Impact factor: 9.776

4.  Tailored porous silicon microparticles: fabrication and properties.

Authors:  Ciro Chiappini; Ennio Tasciotti; Jean R Fakhoury; Daniel Fine; Lee Pullan; Young-Chung Wang; Lianfeng Fu; Xuewu Liu; Mauro Ferrari
Journal:  Chemphyschem       Date:  2010-04-06       Impact factor: 3.102

5.  Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.

Authors:  Jörg Kreuter; Dmitry Shamenkov; Valery Petrov; Peter Ramge; Klaus Cychutek; Claudia Koch-Brandt; Renad Alyautdin
Journal:  J Drug Target       Date:  2002-06       Impact factor: 5.121

Review 6.  Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats.

Authors:  Michelle Longmire; Peter L Choyke; Hisataka Kobayashi
Journal:  Nanomedicine (Lond)       Date:  2008-10       Impact factor: 5.307

7.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions.

Authors:  Alessandro Parodi; Nicoletta Quattrocchi; Anne L van de Ven; Ciro Chiappini; Michael Evangelopoulos; Jonathan O Martinez; Brandon S Brown; Sm Z Khaled; Iman K Yazdi; Maria Vittoria Enzo; Lucas Isenhart; Mauro Ferrari; Ennio Tasciotti
Journal:  Nat Nanotechnol       Date:  2012-12-16       Impact factor: 39.213

8.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface.

Authors:  Anna Salvati; Andrzej S Pitek; Marco P Monopoli; Kanlaya Prapainop; Francesca Baldelli Bombelli; Delyan R Hristov; Philip M Kelly; Christoffer Åberg; Eugene Mahon; Kenneth A Dawson
Journal:  Nat Nanotechnol       Date:  2013-01-20       Impact factor: 39.213

9.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

Review 10.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

View more
  1014 in total

1.  Capsule-Integrated Polypeptide Multilayer Films for Effective pH-Responsive Multiple Drug Co-Delivery.

Authors:  Shichao Zhang; Malcolm Xing; Bingyun Li
Journal:  ACS Appl Mater Interfaces       Date:  2018-12-14       Impact factor: 9.229

2.  Biodistribution of Filamentous Plant Virus Nanoparticles: Pepino Mosaic Virus versus Potato Virus X.

Authors:  Duc H T Le; Eduardo Méndez-López; Chao Wang; Ulrich Commandeur; Miguel A Aranda; Nicole F Steinmetz
Journal:  Biomacromolecules       Date:  2018-12-18       Impact factor: 6.988

3.  Sequential delivery of erlotinib and doxorubicin for enhanced triple negative Breast cancer treatment using polymeric nanoparticle.

Authors:  Zilan Zhou; Carly Kennell; Mina Jafari; Joo-Youp Lee; Sasha J Ruiz-Torres; Susan E Waltz; Jing-Huei Lee
Journal:  Int J Pharm       Date:  2017-08-01       Impact factor: 5.875

4.  Cathepsin-Mediated Cleavage of Peptides from Peptide Amphiphiles Leads to Enhanced Intracellular Peptide Accumulation.

Authors:  Handan Acar; Ravand Samaeekia; Mathew R Schnorenberg; Dibyendu K Sasmal; Jun Huang; Matthew V Tirrell; James L LaBelle
Journal:  Bioconjug Chem       Date:  2017-08-24       Impact factor: 4.774

5.  Investigation into the Biological Impact of Block Size on Cathepsin S-Degradable HPMA Copolymers.

Authors:  Wei Fan; Wenting Zhang; Yinnong Jia; Susan K Brusnahan; Jered C Garrison
Journal:  Mol Pharm       Date:  2017-03-21       Impact factor: 4.939

6.  Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery.

Authors:  Jamie L Betker; Dallas Jones; Christine R Childs; Karen M Helm; Kristina Terrell; Maria A Nagel; Thomas J Anchordoquy
Journal:  J Control Release       Date:  2018-07-17       Impact factor: 9.776

7.  Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease.

Authors:  Jonathan Wang; Jacqueline J Masehi-Lano; Eun Ji Chung
Journal:  Biomater Sci       Date:  2017-07-25       Impact factor: 6.843

8.  Collagenase-Cleavable Peptide Amphiphile Micelles as a Novel Theranostic Strategy in Atherosclerosis.

Authors:  Deborah D Chin; Christopher Poon; Noah Trac; Jonathan Wang; Jackson Cook; Johan Joo; Zhangjingyi Jiang; Naomi Sulit Sta Maria; Russell E Jacobs; Eun Ji Chung
Journal:  Adv Ther (Weinh)       Date:  2020-02-03

9.  Shape-Dependent Biodistribution of Biocompatible Silk Microcapsules.

Authors:  Sisi Cao; Rui Tang; Gail Sudlow; Zheyu Wang; Keng-Ku Liu; Jingyi Luan; Sirimuvva Tadepalli; Anushree Seth; Samuel Achilefu; Srikanth Singamaneni
Journal:  ACS Appl Mater Interfaces       Date:  2019-01-28       Impact factor: 9.229

10.  Speciation of Phenanthriplatin and Its Analogs in the Core of Tobacco Mosaic Virus.

Authors:  Amit A Vernekar; Gilles Berger; Anna E Czapar; Frank A Veliz; David I Wang; Nicole F Steinmetz; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2018-03-19       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.